Halucenex Life Sciences

Cannabis company Creso Pharma (OTCMKTS: COPHF)’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc. shared promising early findings on its ongoing Phase 2 clinical trial assessing the efficacy of psilocybin on treatment-resistant PTSD.  The single-arm, open-lab study tests...

KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc. (OTC: KONEF), has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelics subsidiary of Creso Pharma (OTC: COPHF) developing phase 2...

A number of financial firms and investment banks initiated coverage of Atai Life Sciences (NASDAQ: ATAI) last week. Ratings ranged from a sober sector performance rating from RBC Capital Markets with a $19 12-month price target to a bullish Overweight rating from Cantor Fitzgerald,...